[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597615":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":32,"overallOfficials":11,"centralContacts":40,"locations":11,"responsibleParty":46,"collaborators":11,"id":48,"slug":11,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":11},{"fullName":5,"class":6},"Menzies School of Health Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"incidence risk (time to first event) of any P. vivax parasitaemia",null,"4 months",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20,25,28],{"label":21,"type":22,"description":11,"interventionNames":23},"Tafenoquine plus DHA-Piperaquine","EXPERIMENTAL",[24],"Drug: Tafenoquine plus DHA-Piperaquine",{"label":26,"type":27,"description":11,"interventionNames":11},"DHA-Piperaquine","NO_INTERVENTION",{"label":29,"type":22,"description":11,"interventionNames":30},"Tafenoquine plus artesunate-pyronaridine",[31],"Drug: Tafenoquine plus Artesunate-pyronaridine",[33,37],{"type":34,"name":21,"description":35,"armGroupLabels":36,"otherNames":11},"DRUG","Tafenoquine plus DHA-piperaquine",[21],{"type":34,"name":38,"description":38,"armGroupLabels":39,"otherNames":11},"Tafenoquine plus Artesunate-pyronaridine",[29],[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Hellen Mnjala","CONTACT","000","hellen.mnjala@menzies.edu.au",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100597615",false,"NCT07060794","Tafenoquine and ACTs (TADORE- Plus)","TADORE+","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia (mono-infection)\n* G6PD normal status (G6PD activity ≥70% of the adjusted male median\n* as determined by the Standard G6PD (SD Biosensor, ROK))\n* Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n* Age ≥18 years\n* Haemoglobin at presentation ≥8g\u002Fdl\n* Written informed consent.\n* Living in the study area and willing to be followed for six months\n\nExclusion Criteria:\n\n* Danger signs or symptoms of severe malaria\n* Pregnant or lactating females\n* Regular use of drugs with haemolytic potential\n* Known hypersensitivity to any of the study drugs\n* History of any psychiatric disorder","ALL","18 Years",{"count":57,"type":58},507,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).",[64],"Vivax Malaria","NOT_YET_RECRUITING","2026-03-16",{"date":68,"type":69},"2026-03-18","ACTUAL",{"date":71,"type":58},"2026-06",{"date":73,"type":58},"2028-06",{"name":5,"class":6}]